GI Innovation (358570) Fundamentals 2026 — Revenue Analysis | SniperIQ
GI Innovation (358570) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩451.5B, trading at ₩7030.00 on the KOE. This SniperIQ fundamentals page covers GI Innovation's valuation, profitability (net margin -615.9%), revenue (₩5.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is GI Innovation's market cap?
GI Innovation (358570) has a market capitalization of approximately ₩451.5B, trading at ₩7030.00 on the KOE. Market cap moves with the live share price.
What is GI Innovation's P/E ratio?
GI Innovation's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is GI Innovation?
GI Innovation runs a net profit margin of -615.9%, a gross margin of 68.1%, and an operating margin of -743.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does GI Innovation generate?
GI Innovation reported revenue of ₩5.8B for fiscal year 2025, with net income of -₩35.1B and earnings per share (EPS) of -556.15. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does GI Innovation pay a dividend?
GI Innovation does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is GI Innovation financially healthy?
GI Innovation carries a debt-to-equity ratio of 0.02x and a current ratio of 4.69x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is GI Innovation a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For GI Innovation (358570) the key facts are: market cap ₩451.5B, revenue ₩5.8B, 52-week range 6760-21550. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track GI Innovation's full fundamentals live
Get GI Innovation's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.